Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The Lancet (British edition) 1995-01, Vol.345 (8941), p.29-30
Hauptverfasser:	Howell, A., DeFriend, D.J., Blamey, R.W., Robertson, J.F., Walton, P.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Breast cancer Breast Neoplasms - drug therapy Chemotherapy Drug therapy Drug Tolerance Estradiol - analogs & derivatives Estradiol - therapeutic use Estrogen Antagonists - therapeutic use Estrogens Female Fulvestrant Humans Injections, Intramuscular Medical research Medical sciences Pharmacology. Drug treatments Tamoxifen - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We treated 19 patients with advanced breast cancer resistant to tamoxifen with a new specific antioestrogen (ICI 182780) which, in animal studies, has no agonist activity. 13 (69%) patients responded (7 had partial responses and 6 showed no change) to monthly intramuscular injections of ICI 182780 after progression on tamoxifen, for a median duration of 18 months with minimum side effects. Preliminary evidence suggests that the agent is without effects on the liver or the hypothalamic-pituitary axis. ICI 182780 appears to be a promising new agent for treatment of advanced and early breast cancer.
ISSN:	0140-6736 1474-547X
DOI:	10.1016/S0140-6736(95)91156-1